{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:17:54Z","timestamp":1767910674827,"version":"3.49.0"},"reference-count":29,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>One-year outcomes after therapy with ledipasvir\/sofosbuvir (LDV\/SOF) in children with chronic hepatitis C (CHC) presenting with and without significant liver fibrosis were analyzed. We included patients aged 12\u201317 years treated with LDV\/SOF, presenting with significant fibrosis (F \u2265 2 on the METAVIR scale) in transient elastography (TE) at the baseline and we compared the outcomes with that of patients without fibrosis. Patients were followed every 4 weeks during the treatment, at the end of the therapy, at week 12 posttreatment, and one year after the end of treatment. Liver fibrosis was established using noninvasive methods: TE, aspartate transaminase-to-platelet ratio index (APRI), and Fibrosis-4 index (FIB-4). There were four patients with significant fibrosis at baseline: one with a fibrosis score of F2 on the METAVIR scale, and three with cirrhosis (F4) at baseline. One year after the end of treatment, the hepatitis C viral load was undetectable in three of them. One patient was lost to follow-up after week 4. In two out of the four patients, a significant improvement and regression of liver fibrosis was observed (from stage F4 and F2 to F0-F1 on the METAVIR scale). In one patient, the liver stiffness measurement median increased 12 weeks after the end of the treatment and then decreased, but still correlated with stage F4. An improvement in the APRI was observed in all patients. In four patients without fibrosis, the treatment was effective and no progression of fibrosis was observed. A one-year observation of teenagers with CHC and significant fibrosis treated with LDV\/SOF revealed that regression of liver fibrosis is possible, but not certain. Further observations in larger groups of patients are necessary to find predictors of liver fibrosis regression.<\/jats:p>","DOI":"10.3390\/v13081518","type":"journal-article","created":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T21:46:44Z","timestamp":1627854404000},"page":"1518","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["One-Year Outcomes after Ledipasvir\/Sofosbuvir Treatment of Chronic Hepatitis C in Teenagers with and without Significant Liver Fibrosis\u2014A Case Series Report"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7783-6904","authenticated-orcid":false,"given":"Maria","family":"Pokorska-\u015apiewak","sequence":"first","affiliation":[{"name":"Department of Children\u2019s Infectious Diseases, Medical University of Warsaw, 01-201 Warsaw, Poland"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, 01-201 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Dobrzeniecka","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, 01-201 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5731-6346","authenticated-orcid":false,"given":"Magdalena","family":"Marczy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Children\u2019s Infectious Diseases, Medical University of Warsaw, 01-201 Warsaw, Poland"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, 01-201 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1053\/j.gastro.2008.02.082","article-title":"Long-term course of chronic hepatitis C in children: From viral clearance to end-stage liver disease","volume":"134","author":"Bortolotti","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"The European Paediatric Hepatitis C Virus Network (2005). Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin. Infect. Dis., 41, 45\u201351.","DOI":"10.1086\/430601"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1086\/345908","article-title":"Chronic Hepatitis C Virus Infection in Childhood: Clinical Patterns and Evolution in 224 White Children","volume":"36","author":"Jara","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5114\/pjp.2015.57248","article-title":"Determinants of liver disease progression in children with chronic hepatitis C virus infection","volume":"4","author":"Aniszewska","year":"2015","journal-title":"Pol. J. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1572-0241.2003.07293.x","article-title":"Fibrosis in Chronic Hepatitis C Acquired in Infancy: Is It Only a Matter of Time?","volume":"98","author":"Guido","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/INF.0000000000002913","article-title":"Liver Fibrosis Evaluated With Transient Elastography in 35 Children with Chronic Hepatitis C Virus Infection","volume":"40","author":"Dobrzeniecka","year":"2021","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/jvh.13093","article-title":"Advanced liver disease in Russian children and adolescents with chronic hepatitis C","volume":"26","author":"Turkova","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2018.11.013","article-title":"Epidemiology and natural history of hepatitis C virus infection among children and young people","volume":"70","author":"Modin","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/apt.16037","article-title":"Systematic review with meta-analysis: The efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection","volume":"52","author":"Indolfi","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jpeds.2021.02.012","article-title":"Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals","volume":"233","author":"Mogahed","year":"2021","journal-title":"J. Pediatr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MPG.0000000000001872","article-title":"Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"66","author":"Indolfi","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zeng, J., Zhang, X., Sun, C., Pan, Q., Lu, W.-Y., Chen, Q., Huang, L.-S., and Fan, J.-G. (2019). Feasibility study and reference values of FibroScan 502 with M probe in healthy preschool children aged 5 years. BMC Pediatr., 19.","DOI":"10.1186\/s12887-019-1487-6"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Vergniol","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clinre.2011.08.001","article-title":"The controlled attenuation parameter (CAP): A novel tool for the non-invasive evaluation of steatosis using Fibroscan\u00ae","volume":"36","author":"Sasso","year":"2012","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis","volume":"53","author":"Lin","year":"2010","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hep.28995","article-title":"The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12\u201317 years old with hepatitis C virus genotype 1 infection","volume":"66","author":"Balistreri","year":"2017","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.30830","article-title":"Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old with Chronic Hepatitis C","volume":"71","author":"Schwarz","year":"2020","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/hep.30123","article-title":"Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11","volume":"68","author":"Murray","year":"2018","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3748\/wjg.v27.i12.1117","article-title":"Cascade of care for children and adolescents with chronic hepatitis C","volume":"27","author":"Rogers","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Chen, S.-H., Lai, H.-C., Chen, S.-H., Chiang, W.-P., Su, S.-H., Lin, C.-H., Kao, J.-T., Chuang, P.-H., Hsu, W.-F., and Wang, H.-W. (2018). Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0190455"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MOG.0000000000000524","article-title":"Fibrosis reversal after hepatitis C virus elimination","volume":"35","author":"Rockey","year":"2019","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/jvh.12578","article-title":"Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy","volume":"23","author":"Knop","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index","volume":"37","author":"Bachofner","year":"2017","journal-title":"Liver Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.hbpd.2020.06.013","article-title":"Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis\/cirrhosis patients in Australia","volume":"19","author":"Chan","year":"2020","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jpids\/piaa006","article-title":"Ledipasvir\/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness","volume":"10","author":"Makhlouf","year":"2021","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1097\/QAD.0000000000001966","article-title":"Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection","volume":"32","author":"Carrasco","year":"2018","journal-title":"AIDS"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4254\/wjh.v12.i8.485","article-title":"Management of hepatitis C in children and adolescents during COVID-19 pandemic","volume":"12","year":"2020","journal-title":"World J. Hepatol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1518\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:38:40Z","timestamp":1760164720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,31]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["v13081518"],"URL":"https:\/\/doi.org\/10.3390\/v13081518","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,31]]}}}